| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCBLD2 |
| Uniprot No | Q96PD2-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-482aa |
| 氨基酸序列 | MASRAVVRAR RCPQCPQVRA AAAAPAWAAL PLSRSLPPCS NSSSFSMPLF LLLLLVLLLL LEDAGAQQGD GCGHTVLGPE SGTLTSINYP QTYPNSTVCE WEIRVKMGER VRIKFGDFDI EDSDSCHFNY LRIYNGIGVS RTEIGKYCGL GLQMNHSIES KGNEITLLFM SGIHVSGRGF LASYSVIDKQ DLITCLDTAS NFLEPEFSKY CPAGCLLPFA EISGTIPHGY RDSSPLCMAG VHAGVVSNTL GGQISVVISK GIPYYESSLA NNVTSVVGHL STSLFTFKTS GCYGTLGMES GVIADPQITA SSVLEWTDHT GQENSWKPKK ARLKKPGPPW AAFATDEYQW LQIDLNKEKK ITGIITTGST MVEHNYYVSA YRILYSDDGQ KWTVYREPGV EQDKIFQGNK DYHQDVRNNF LPPIIARFIR VNPTQWQQKI AMKMELLGCQ FIPKGRPPKL TQPPPPRNSN DLKNTTAPPK IA |
| 预测分子量 | 53 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCBLD2重组蛋白的3篇参考文献的简要信息(注：文献为示例性内容，实际研究中请以真实数据库检索结果为准)：
---
1. **文献名称**: *DCBLD2 modulates vascular endothelial growth factor receptor signaling in endothelial cells*
**作者**: Smith A, et al.
**摘要**: 本研究通过重组DCBLD2蛋白体外实验，发现其与VEGFR2受体结合并增强血管内皮生长因子(VEGF)介导的血管生成信号。研究揭示了DCBLD2在病理性血管生成中的潜在作用。
---
2. **文献名称**: *Recombinant DCBLD2 promotes tumor cell migration via EGFR interaction*
**作者**: Chen L, et al.
**摘要**: 作者通过表达并纯化重组DCBLD2蛋白，证明其能通过结合表皮生长因子受体(EGFR)激活下游MAPK通路，促进肿瘤细胞迁移，提示其在癌症转移中的机制。
---
3. **文献名称**: *Structural characterization of DCBLD2 recombinant protein and its role in neurodevelopment*
**作者**: Wang Y, et al.
**摘要**: 本研究解析了重组DCBLD2蛋白的晶体结构，发现其LCCL结构域参与神经突触形成。体外实验表明，重组蛋白可调节神经元轴突导向，为神经系统疾病提供新靶点。
---
如需获取真实文献，建议通过PubMed或Google Scholar搜索关键词“DCBLD2 recombinant protein”或结合具体研究领域筛选。
**Background of DCBLD2 Recombinant Protein**
DCBLD2 (Discoidin, CUB and LCCL domain-containing protein 2), also known as CLCP1 or ESDN, is a transmembrane glycoprotein implicated in cell adhesion, signaling, and extracellular matrix interactions. It belongs to the neuropilin-like protein family and shares structural homology with neuropilins, particularly in its discoidin-like domains. The protein is composed of two discoidin-like domains at the N-terminus, a CUB domain, and a short cytoplasmic tail, suggesting roles in ligand binding and intercellular communication.
DCBLD2 is expressed in various tissues, including vascular endothelium, neurons, and certain epithelial cells. Its biological functions remain under active investigation, but studies link it to angiogenesis, tumor progression, and cardiovascular development. For instance, DCBLD2 interacts with receptor tyrosine kinases (e.g., EGFR, PDGFR) and modulates their signaling pathways, influencing cell migration, proliferation, and survival. Elevated DCBLD2 expression has been observed in cancers like non-small cell lung carcinoma and glioblastoma, correlating with poor prognosis and metastatic potential.
Recombinant DCBLD2 protein is engineered for *in vitro* and *in vivo* studies to dissect its molecular mechanisms. Produced via heterologous expression systems (e.g., mammalian cells, *E. coli*), it retains functional domains for binding assays, structural studies, or antibody development. Researchers utilize it to explore DCBLD2's role in pathological processes, such as tumor angiogenesis or fibrosis, and to screen therapeutic agents targeting its activity. Challenges include preserving post-translational modifications (e.g., glycosylation) critical for its interactions.
Overall, DCBLD2 recombinant protein serves as a vital tool for unraveling its physiological and pathological significance, with potential applications in diagnostics and targeted therapy development.
×
